| NCT02951728 | Ruijin Hospital | Diffuse Large B Cell Lymphoma | 2016-10 | PHASE1|PHASE2 |
| NCT03111069 | M.D. Anderson Cancer Center | Malignant Neoplasms of Mesothelial and Soft Tissue|Rhabdomyosarcoma, Pelvic|Rhabdomyosarcoma, Abdominal | 2018-08 | PHASE1 |
| NCT04358341 | Sixth Affiliated Hospital, Sun Yat-sen University | Gastric Cancer | 2020-06-17 | PHASE2 |
| NCT00002477 | Medical Research Council | Ovarian Cancer | 1991-04 | PHASE3 |
| NCT00092222 | National Cancer Institute (NCI) | Lymphoproliferative Disorder|HHV-8|Malignancy|HIV | 2004-10-28 | PHASE2 |
| NCT01992653 | Genentech, Inc. | Lymphoma, Non Hodgkin | 2013-11-29 | PHASE1|PHASE2 |
| NCT00923936 | National Cancer Institute (NCI) | Sarcoma, Kaposi | 2009-04-23 | PHASE2 |
| NCT00290667 | German High-Grade Non-Hodgkin´s Lymphoma Study Group | Lymphoma | 2004-02 | PHASE2 |
| NCT00216645 | Janssen Pharmaceutical K.K. | Ovarian Neoplasms | 2005-01 | PHASE2 |
| NCT07286331 | GlaxoSmithKline|European Network of Gynaecological Oncological Trial Groups (ENGOT)|GOG Foundation | Neoplasms, Endometrial | 2026-06-09 | PHASE3 |
| NCT05824975 | GI Innovation, Inc.|Merck Sharp & Dohme LLC | Advanced Solid Tumor|Metastatic Solid Tumor|Soft Tissue Sarcoma (STS)|Platinum-resistant Ovarian Cancer (PROC)|Hepatocellular Carcinoma (HCC)|Colorectal Cancer (CRC)|HER2 Negative Breast Cancer|Cutaneous Melanoma|Renal Cell Carcinoma (RCC) | 2023-05-30 | PHASE1|PHASE2 |
| NCT02659930 | National Cancer Institute (NCI) | Kaposi Sarcoma | 2016-01-13 | PHASE1 |
| NCT00002802 | Children´s Hospital Medical Center, Cincinnati | Neuroblastoma | 1990-07 | PHASE3 |
| NCT01177683 | Sherif Farag, MB, BS|Hoosier Cancer Research Network|Cephalon, Inc. | Multiple Myeloma | 2010-07 | PHASE1|PHASE2 |
| NCT00004039 | Hoag Memorial Hospital Presbyterian|Cancer Biotherapy Research Group | Lymphoma | 1998-06 | PHASE2 |
| NCT04301739 | Shanghai Henlius Biotech | Triple Negative Breast Cancer | 2020-04-17 | PHASE3 |
| NCT00712881 | Cephalon, Inc. | Breast Cancer | 2008-10-13 | PHASE2 |
| NCT07081022 | Shanghai Junshi Bioscience Co., Ltd. | B-cell Non-Hodgkin´s Lymphoma | 2025-08-17 | PHASE2 |
| NCT02877303 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma | 2016-11-01 | PHASE2 |
| NCT00574236 | University of Wisconsin, Madison|National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc. | Metastatic Breast Cancer | 2006-08 | PHASE2 |
| NCT00877006 | Teva Branded Pharmaceutical Products R&D, Inc. | Non-Hodgkin´s Lymphoma|Mantle Cell Lymphoma | 2009-04-30 | PHASE3 |
| NCT05207514 | Samyang Biopharmaceuticals Corporation | Breast Cancer | 2022-03-31 | PHASE3 |
| NCT05279300 | CStone Pharmaceuticals | Advanced Solid Tumor|Advanced Lymphoma | 2022-03-28 | PHASE1 |
| NCT02228512 | National Cancer Institute (NCI) | Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease|Primary Effusion Lymphoma | 2014-08-15 | PHASE1|PHASE2 |
| NCT05291338 | Rehab Werida | Hepatocellular Carcinoma | 2022-01-01 | |
| NCT00578864 | Baylor College of Medicine | Neuroblastoma | 2007-03 | PHASE2 |
| NCT05976932 | Fudan University | Ovarian Cancer | 2023-08 | |
| NCT03020030 | Dana-Farber Cancer Institute|Servier | Acute Lymphoblastic Leukemia, Pediatric | 2017-03-03 | PHASE3 |
| NCT05406401 | Merck Sharp & Dohme LLC | Lymphoma, Large B-Cell, Diffuse (DLBCL) | 2022-07-14 | PHASE2 |
| NCT00003119 | Children´s Oncology Group|National Cancer Institute (NCI) | Neuroblastoma | 1998-03 | PHASE3 |
| NCT00726700 | Universit?t des Saarlandes | Lymphoma | 2004-05 | PHASE2 |
| NCT00022230 | Roger Williams Medical Center | Breast Cancer | 2000-01 | PHASE1|PHASE2 |
| NCT00028964 | University of California, San Francisco|National Cancer Institute (NCI) | Breast Cancer|Drug+Agent Toxicity by Tissue+Organ | 2001-02 | PHASE1|PHASE2 |
| NCT00002744 | Children´s Oncology Group|National Cancer Institute (NCI) | Leukemia | 1996-05 | PHASE3 |
| NCT05630209 | InSightec | Brain Tumor | 2023-01-04 | PHASE1|PHASE2 |
| NCT00004092 | City of Hope Medical Center|National Cancer Institute (NCI) | Breast Cancer | 1999-05 | PHASE2 |
| NCT01746992 | Ruijin Hospital | ALK-negative Anaplastic Large Cell Lymphoma|Peripherial T Cell Lymphoma,Not Otherwise Specified|Angioimmunoblastic T Cell Lymphoma|Enteropathy Associated T Cell Lymphoma|Hepatosplenic T Cell Lymphoma|Subcutaneous Panniculitis Like T Cell Lymphoma | 2012-09 | PHASE4 |
| NCT00410631 | German Society for Pediatric Oncology and Hematology GPOH gGmbH | Neuroblastoma | 2004-10 | PHASE3 |
| NCT00039195 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Bristol-Myers Squibb|Genentech, Inc. | Lymphoma | 2006-11 | PHASE2 |
| NCT00431795 | Hellenic Oncology Research Group|University Hospital of Crete | Breast Cancer | 2003-06 | PHASE2 |
| NCT02312245 | Mayo Clinic|National Cancer Institute (NCI) | Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma | 2015-07-21 | PHASE2 |
| NCT01042041 | Abramson Cancer Center at Penn Medicine | Hepatocellular Carcinoma|Liver Cancer|Localized Unresectable Liver Cancer | 2009-09 | PHASE1 |
| NCT00004231 | Northwestern University|National Cancer Institute (NCI) | Lymphoma | 1999-10 | PHASE2 |
| NCT00542191 | Leo W. Jenkins Cancer Center | Breast Cancer | 2007-07 | PHASE2 |
| NCT04757337 | UNICANCER | Advanced Soft-tissue Sarcoma|Metastatic Soft-tissue Sarcoma | 2021-06-18 | PHASE3 |
| NCT01338753 | Clinica Universidad de Navarra, Universidad de Navarra|Roche Farma, S.A | Breast Neoplasms | 2009-10 | PHASE2 |
| NCT00968253 | M.D. Anderson Cancer Center|Novartis | Leukemia|Acute Lymphocytic Leukemia | 2009-11 | PHASE1|PHASE2 |
| NCT00119262 | National Cancer Institute (NCI) | Male Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer | 2005-10 | PHASE2 |
| NCT03211117 | Mayo Clinic|National Cancer Institute (NCI) | Thyroid Gland Undifferentiated (Anaplastic) Carcinoma | 2017-08-14 | PHASE2 |
| NCT00755313 | University of California, San Francisco|National Cancer Institute (NCI) | Breast Cancer|Chemotherapeutic Agent Toxicity|Cognitive+Functional Effects|Fatigue|Long-term Effects Secondary to Cancer Therapy in Adults|Neurotoxicity|Psychosocial Effects of Cancer and Its Treatment | 2007-05 | |
| NCT07545460 | Sichuan Baili Pharmaceutical Co., Ltd.|Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer | 2026-04 | PHASE3 |
| NCT03734068 | International Group of Endovascular Oncology | Hepatocellular Carcinoma | 2018-06-13 | |
| NCT02792491 | Pusan National University Hospital | Diffuse Large B-cell Lymphoma | 2012-08 | PHASE2 |
| NCT04996160 | Tanja Andrea Gruber | Acute Lymphoblastic Leukemia, Pediatric|Relapsed Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia | 2021-07-09 | PHASE1 |
| NCT00990860 | Taipei Veterans General Hospital, Taiwan | Hepatocellular Carcinoma | 2009-02 | PHASE2 |
| NCT05389423 | National Cancer Institute (NCI) | Diffuse Large Cell Lymphoma|Non-Hodgkin Lymphoma|Burkitt Lymphoma|Plasmablastic Lymphoma|B-Cell Neoplasm | 2023-06-27 | PHASE1 |
| NCT00011986 | Gynecologic Oncology Group|SWOG Cancer Research Network|Medical Research Council|National Cancer Institute (NCI) | Primary Peritoneal Carcinoma|Stage III Ovarian Cancer|Stage IV Ovarian Cancer | 2001-01 | PHASE3 |
| NCT01750073 | University of Nebraska|National Cancer Institute (NCI) | Estrogen Receptor Negative|Estrogen Receptor Positive|HER2+Neu Negative|HER2+Neu Positive|Invasive Breast Carcinoma|Progesterone Receptor Negative|Progesterone Receptor Positive|Stage IA Breast Cancer|Stage II Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-Negative Breast Carcinoma | 2012-12-07 | PHASE2 |
| NCT00002766 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) | Leukemia|Lymphoma | 1996-03 | PHASE3 |
| NCT06563245 | Children´s Cancer Group, China|Shanghai Children´s Medical Center|Najing Children´s Hospital|West China Second University Hospital|Qilu Hospital of Shandong University|Tianjin Medical University Cancer Institute and Hospital|Tongji Hospital|Xiangya Hospital of Central South University|The First Affiliated Hospital of Zhengzhou University|The Second Hospital of Anhui Medical University|Children´s Hospital of Hebei Province|Children´s Hospital of Henan Province|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Classical Hodgkin Lymphoma|Child|Adolescent|Young Adult|Metabolic Response|Survival|Treatment|Brentuximab Vedotin|PET Scan | 2024-09-25 | PHASE2|PHASE3 |
| NCT00004888 | National Cancer Institute (NCI) | Recurrent Breast Cancer|Stage IV Breast Cancer | 2001-01 | PHASE2 |
| NCT01016054 | Astellas Pharma Inc|Agensys, Inc. | Carcinoma|Ovarian Cancer|Ovarian Diseases|Ovarian Neoplasms | 2009-10 | PHASE1 |
| NCT06835049 | Swiss Cancer Institute | Sarcoma,Soft Tissue | 2025-10-27 | PHASE2 |
| NCT01920932 | St. Jude Children´s Research Hospital|Seagen Inc. | Stage II Childhood Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma | 2013-08-12 | PHASE2 |
| NCT07220187 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Richter Syndrome|Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma|Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma | 2026-05-02 | PHASE3 |
| NCT00550771 | Merck Sharp & Dohme LLC | Breast Neoplasm | 2007-07-16 | PHASE2 |
| NCT03949634 | Fudan University | Early Breast Cancer | 2017-09-01 | PHASE3 |
| NCT02626455 | Bayer | Lymphoma, Non-Hodgkin | 2016-01-06 | PHASE3 |
| NCT01872416 | The First Affiliated Hospital of Guangzhou Medical University | Small Cell Lung Cancer | 2012-10 | PHASE2 |
| NCT00005024 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | | PHASE3 |
| NCT00657878 | National Cancer Institute, Naples | Ovarian Cancer | 2008-11 | PHASE3 |
| NCT02451943 | Eli Lilly and Company | Soft Tissue Sarcoma | 2015-09-14 | PHASE3 |
| NCT05681260 | Children´s Cancer Group, China|Shanghai Children´s Medical Center|Beijing Children´s Hospital|Children´s Hospital of Scow University|West China Second University Hospital|Nanjing Children´s Hospital|Qilu Hospital of Shandong University|Tianjin Medical University Cancer Institute and Hospital|Tongji Hospital|Xiangya Hospital of Central South University|The First Affiliated Hospital of Zhengzhou University|Cancer hospital of Shandong Province|Shenzhen Children´s Hospital|Wuhan Children´s Hospital|The Children´s Hospital of Zhejiang University School of Medicine|Shanghai Children´s Hospital|Ruijin Hospital|The Second Hospital of Anhui Medical University|Children´s Hospital of Hebei Province|Cancer Hospital of Henan Province|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Qilu Children´s Hospital | T-cell Lymphoblastic Lymphoma | 2023-02-06 | PHASE3 |
| NCT00516750 | Kyoto University | Bladder Cancer | 2007-07 | PHASE2 |
| NCT02957968 | Virginia Commonwealth University|Merck Sharp & Dohme LLC|National Cancer Institute (NCI) | Breast Adenocarcinoma|Estrogen Receptor- Negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|HER2+Neu Negative|Invasive Breast Carcinoma|Progesterone Receptor Negative|Progesterone Receptor Positive Tumor|Stage II Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Triple-negative Breast Carcinoma | 2017-01-24 | PHASE2 |
| NCT00005090 | SWOG Cancer Research Network|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B | Lymphoma | 2000-04 | PHASE3 |
| NCT02055820 | Hoffmann-La Roche|AbbVie | Lymphoma, Non-Hodgkin | 2013-11-17 | PHASE1|PHASE2 |
| NCT01451515 | St. Jude Children´s Research Hospital|National University of Singapore | Lymphoblastic Lymphoma | 2012-05-25 | PHASE2 |
| NCT00186849 | St. Jude Children´s Research Hospital|National Institutes of Health (NIH) | Neuroblastoma | 1997-10 | PHASE2 |
| NCT05287308 | Chinese Academy of Medical Sciences|CSPC Ouyi Pharmaceutical Co., Ltd. | Breast Cancer | 2022-03 | NA |
| NCT00235235 | Hoosier Cancer Research Network|United States Department of Defense|Indiana University|Walther Cancer Institute | Breast Cancer | 2005-09 | |
| NCT04038489 | University of Virginia | Breast Cancer|Estrogen Receptor-positive Breast Cancer | 2019-10-18 | PHASE2 |
| NCT05467670 | Alexander B Olawaiye, MD|ALX Oncology|Merck Sharp & Dohme LLC | Ovarian Cancer | 2023-03-30 | PHASE2 |
| NCT05888493 | Novartis Pharmaceuticals | Follicular Lymphoma (FL) | 2023-10-02 | PHASE3 |
| NCT00886028 | National Institute of Cancerología | Malignant Pleural Mesothelioma | 2006-09 | PHASE2 |
| NCT00039130 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Leukemia|Lymphoma | 2002-05 | PHASE2 |
| NCT04043494 | University Hospital Muenster|Deutsche Krebshilfe e.V., Bonn (Germany) | Lymphoblastic Lymphoma, Childhood | 2019-08-23 | PHASE3 |
| NCT01334502 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Lymphoma | 2012-03 | PHASE1 |
| NCT00779129 | Merck Sharp & Dohme LLC|Princess Margaret Hospital, Canada | Breast Neoplasm | 2003-03 | PHASE2 |
| NCT03056001 | Wake Forest University Health Sciences|Merck Sharp & Dohme LLC | Soft Tissue Sarcoma, Adult|Soft Tissue Sarcoma, Child | 2017-05-01 | PHASE2 |
| NCT00890656 | M.D. Anderson Cancer Center|Enzon Pharmaceuticals, Inc. | Acute Lymphoblastic Leukemia | 2003-06 | PHASE2 |
| NCT00777673 | University of Tennessee Cancer Institute|National Comprehensive Cancer Network|Celgene Corporation|Genentech, Inc. | Breast Cancer | 2008-10 | PHASE2 |
| NCT00082472 | Zivena | NSCLC | 2004-01 | PHASE1|PHASE2 |
| NCT00124956 | Boston Children´s Hospital|Glaser Pediatric Research Network|Elizabeth Glaser Pediatric AIDS Foundation | Cancer | 2003-06 | PHASE1|PHASE2 |
| NCT00129376 | Spanish Breast Cancer Research Group|Sanofi | Breast Cancer | 2003-02 | PHASE2 |
| NCT01206881 | Herlev Hospital|Rigshospitalet, Denmark|Odense University Hospital|Aarhus University Hospital | Breast Cancer | 2009-03 | PHASE2 |
| NCT04850495 | Yazeed Sawalha | Diffuse Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma | 2021-11-16 | PHASE1 |
| NCT06954805 | Jennifer Amengual|The Leukemia and Lymphoma Society | Lymphoma|Lymphoma, B-Cell | 2025-04-14 | PHASE2 |
| NCT01537029 | Texas Tech University Health Sciences Center|University of Texas | Breast Cancer|Obesity | 2012-02 | PHASE4 |
| NCT00369681 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) | Lymphoma | 2006-05 | PHASE2 |
| NCT03425656 | AryoGen Pharmed Co. | Malignant Neoplasm of Breast | 2016-07-09 | PHASE3 |
| NCT02735928 | Catholic University of the Sacred Heart | Ovarian Epithelial Cancer Recurrent|Platinum-resistant | 2016-01 | NA |
| NCT01767155 | AEterna Zentaris | Endometrial Cancer | 2013-04 | PHASE3 |
| NCT01327521 | Albert Koong|Accuray Incorporated | Carcinoma, Hepatocellular | 2011-02 | PHASE3 |
| NCT00244985 | Roswell Park Cancer Institute|Ortho Biotech, Inc. | Lymphoma | 2005-09 | PHASE1|PHASE2 |
| NCT00336791 | M.D. Anderson Cancer Center|Breast Cancer Research Foundation | Breast Cancer | 2003-09 | PHASE3 |
| NCT00038610 | M.D. Anderson Cancer Center|Novartis Pharmaceuticals | Leukemia | 2001-03 | PHASE2 |
| NCT00344422 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA | Multiple Myeloma|Myeloma|M-Protein|Myeloma Proteins | 2000-10 | PHASE3 |
| NCT01925612 | Seagen Inc. | Lymphoma, B-cell|Lymphoma, Large B-cell, Diffuse | 2013-08 | PHASE2 |
| NCT01527422 | Fernando Cabanillas|Genzyme, a Sanofi Company | Lymphoma|Non Hodgkin´s Lymphoma | 2006-01 | PHASE1|PHASE2 |
| NCT04980222 | Hoffmann-La Roche | Lymphoma | 2022-03-22 | PHASE2 |
| NCT02648477 | City of Hope Medical Center|National Cancer Institute (NCI)|Merck Sharp & Dohme LLC | Estrogen Receptor Negative|Estrogen Receptor Positive|HER2+Neu Negative|Progesterone Receptor Negative|Progesterone Receptor Positive|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma | 2016-03-28 | PHASE2 |
| NCT02428751 | Wenqi Jiang | Lymphoma, Large B-Cell, Diffuse | 2015-09 | PHASE3 |
| NCT04803201 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Angioimmunoblastic T-cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Follicular T-Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma|Nodal Peripheral T-Cell Lymphoma With TFH Phenotype|Peripheral T-Cell Lymphoma, Not Otherwise Specified | 2021-10-08 | PHASE2 |
| NCT06356129 | Celgene | Large B-cell Lymphoma | 2024-06-19 | PHASE3 |
| NCT06594939 | Medical College of Wisconsin | Diffuse Large B Cell Lymphoma (DLBCL) | 2026-06 | PHASE2 |
| NCT06528496 | Memorial Sloan Kettering Cancer Center | High-risk Neuroblastoma|Neuroblastoma|Childhood Neuroblastoma | 2024-07-22 | PHASE2 |
| NCT07171827 | Helwan University | Anti-CD30|Brentuximab|Doxorubicin|Vinblastine|Dacarbazine|Frontline|Advanced Classical Hodgkin Lymphoma | 2023-03-01 | NA |
| NCT03698227 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Advanced Soft Tissue Sarcoma | 2018-11-12 | PHASE2 |
| NCT03677141 | Hoffmann-La Roche | B-cell Non-Hodgkin Lymphoma | 2019-03-08 | PHASE1|PHASE2 |
| NCT01227941 | Tesaro, Inc. | Ovarian Cancer | 2010-11 | PHASE1 |
| NCT00002791 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group | Sarcoma | 1997-02 | PHASE2 |
| NCT02845882 | Children´s Cancer Group, China|Shanghai Children´s Medical Center|Tongji Hospital|West China Second University Hospital|Qilu Hospital of Shandong University|Tianjin Medical University Cancer Institute and Hospital|Children´s Hospital of Soochow University|Nanjing Children´s Hospital|Xiangya Hospital of Central South University | Lymphoblastic Lymphoma | 2016-01 | PHASE3 |
| NCT00652860 | Mayo Clinic|National Cancer Institute (NCI) | Metastatic Cancer|Sarcoma | 2001-08 | PHASE2 |
| NCT00089544 | National Cancer Institute (NCI)|Radiation Therapy Oncology Group | Recurrent Adult Soft Tissue Sarcoma|Stage I Adult Soft Tissue Sarcoma AJCC v7|Stage II Adult Soft Tissue Sarcoma AJCC v7|Stage III Adult Soft Tissue Sarcoma AJCC v7 | 2004-06-17 | PHASE2 |
| NCT02958163 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Erasme University Hospital|Jules Bordet Institute|University of Liege|Clinique Saint Joseph, Liège|Centre Hospitalier Universitaire UCLouvain Namur | Liver Neoplasms|Hepatocellular Cancer | 2017-02-20 | PHASE2 |
| NCT00003893 | University Hospital Birmingham | Breast Cancer | 1998-07 | PHASE3 |
| NCT01005914 | OHSU Knight Cancer Institute | Leukemia | 2009-06 | PHASE2 |
| NCT00635193 | AbbVie (prior sponsor, Abbott)|Biogen | Ovarian Cancer, Primary Peritoneal Cancer | 2007-07 | PHASE1|PHASE2 |
| NCT00003421 | Medical Research Council | Lymphoma | 1998-06 | PHASE3 |
| NCT05210374 | Case Comprehensive Cancer Center | Relapsed Sarcomas | 2023-03-09 | PHASE1 |
| NCT03340376 | Universitaire Ziekenhuizen KU Leuven|Roche Pharma AG | Cervical Cancer | 2017-08-30 | PHASE2 |
| NCT01227408 | University of Southern California|CTI BioPharma | Breast Cancer | 2009-02 | PHASE2 |
| NCT03003520 | Celgene | Lymphoma, Large B-Cell, Diffuse | 2017-02-28 | PHASE2 |
| NCT01809379 | Ruhr University of Bochum | Recurrent Ovarian Cancer | 2013-02 | PHASE2 |
| NCT00381680 | Children´s Oncology Group|National Cancer Institute (NCI) | B-cell Childhood Acute Lymphoblastic Leukemia|L1 Childhood Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia | 2007-03 | PHASE3 |
| NCT00003380 | Gynecologic Oncology Group|National Cancer Institute (NCI) | Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer | 1998-05 | PHASE1 |
| NCT00580333 | Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital|Genentech, Inc. | Breast Cancer | 2007-09 | PHASE2 |
| NCT00792948 | National Cancer Institute (NCI) | Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Adult L1 Acute Lymphoblastic Leukemia|Adult L2 Acute Lymphoblastic Leukemia|Adult T Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia | 2009-09-01 | PHASE2 |
| NCT00020566 | University of Leicester|National Cancer Institute (NCI)|Children´s Cancer and Leukaemia Group|Societe Francaise Oncologie Pediatrique|European Organisation for Research and Treatment of Cancer - EORTC|German Society for Pediatric Oncology and Hematology GPOH gGmbH|Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria|Swiss Cancer Institute|EBMT Solid Tumors Working Party|Children´s Oncology Group | Sarcoma | 2001-02 | PHASE3 |
| NCT00436566 | Mayo Clinic|National Cancer Institute (NCI) | Breast Cancer|Cardiac Toxicity | 2007-03-16 | PHASE2 |
| NCT01481194 | Vejle Hospital|The University of Hong Kong | Multiple Myeloma | 2011-11 | PHASE2 |
| NCT06377566 | Memorial Sloan Kettering Cancer Center|Seagen Inc. | Hodgkin Lymphoma | 2024-04-17 | PHASE2 |
| NCT00004123 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Sarcoma | 1997-07 | PHASE1 |
| NCT03277924 | Grupo Espanol de Investigacion en Sarcomas | Soft Tissue Sarcoma|Bone Sarcoma | 2017-05-31 | PHASE1|PHASE2 |
| NCT02292979 | The Lymphoma Academic Research Organisation|Millennium Pharmaceuticals, Inc. | Hodgkin Lymphoma | 2015-03 | PHASE2 |
| NCT02561273 | University of Nebraska|National Cancer Institute (NCI) | Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Hepatosplenic T-Cell Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Stage II Angioimmunoblastic T-cell Lymphoma|Stage II Enteropathy-Associated T-Cell Lymphoma|Stage III Angioimmunoblastic T-cell Lymphoma|Stage III Enteropathy-Associated T-Cell Lymphoma|Stage IV Angioimmunoblastic T-cell Lymphoma|Stage IV Enteropathy-Associated T-Cell Lymphoma | 2015-09-28 | PHASE1|PHASE2 |
| NCT02049905 | ImmunityBio, Inc. | Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma | 2014-01 | PHASE3 |
| NCT00003519 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|SWOG Cancer Research Network|North Central Cancer Treatment Group|Cancer and Leukemia Group B | Breast Cancer | 1998-08-20 | PHASE3 |
| NCT06401330 | Children´s Oncology Group | Stage I Mixed Cell Type Kidney Wilms Tumor|Stage II Mixed Cell Type Kidney Wilms Tumor|Stage III Mixed Cell Type Kidney Wilms Tumor|Stage IV Mixed Cell Type Kidney Wilms Tumor | 2025-04-15 | PHASE3 |
| NCT01848132 | Grupo Espa?ol de Linfomas y Transplante Autólogo de Médula ósea|Janssen-Cilag, S.A. | Diffuse, Large B-Cell, Lymphoma | 2013-10-03 | PHASE2 |
| NCT00033644 | Gynecologic Oncology Group|National Cancer Institute (NCI) | Sarcoma | 2002-03 | PHASE2 |
| NCT01131364 | Philogen S.p.A. | Advanced Solid Tumor|Breast Cancer | 2008-06 | PHASE1|PHASE2 |
| NCT03126916 | Children´s Oncology Group|National Cancer Institute (NCI) | Ganglioneuroblastoma|Ganglioneuroblastoma, Nodular|Neuroblastoma | 2018-05-14 | PHASE3 |
| NCT06014528 | InxMed (Shanghai) Co., Ltd. | Ovarian Cancer Recurrent | 2022-09-06 | PHASE2 |
| NCT03409198 | Oslo University Hospital|Bristol-Myers Squibb|Helse Stavanger HF|Helse Sor-Ost|Sorlandet Hospital HF|Jules Bordet Institute|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Centre Hospitalier Universitaire UCLouvain Namur | Breast Cancer|Hormone Receptor Positive Tumor|Metastatic Breast Cancer | 2018-01-21 | PHASE2 |
| NCT00801281 | Polish Lymphoma Research Group | Follicular Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma|Lymphoplasmacytic Lymphoma | 2007-02 | PHASE3 |
| NCT01769209 | Stanford University|National Cancer Institute (NCI) | B-cell Adult Acute Lymphoblastic Leukemia (ALL)|Ph-positive Adult Acute Lymphoblastic Leukemia (ALL)|Recurrent Adult Acute Lymphoblastic Leukemia (ALL)|T-cell Adult Acute Lymphoblastic Leukemia (ALL) | 2013-03 | PHASE2 |
| NCT00744354 | UNC Lineberger Comprehensive Cancer Center|Merck Sharp & Dohme LLC|Millennium Pharmaceuticals, Inc.|Ortho Biotech, Inc. | Multiple Myeloma and Plasma Cell Neoplasm | 2008-10 | PHASE1 |
| NCT07193862 | Northwell Health | Colorectal Cancer Metastatic | 2025-12-10 | EARLY_PHASE1 |
| NCT00000954 | National Institute of Allergy and Infectious Diseases (NIAID)|Novum|Bristol-Myers Squibb | Sarcoma, Kaposi|HIV Infections | | PHASE1 |
| NCT00003679 | Scottish Cancer Therapy Network | Breast Cancer | 1998-11 | PHASE3 |
| NCT00002542 | NCIC Clinical Trials Group | Breast Cancer | 1993-07-20 | PHASE3 |
| NCT00703170 | Washington University School of Medicine | Resistant Solid Malignancies | 2008-03 | PHASE1 |
| NCT00002147 | Sequus Pharmaceuticals | Sarcoma, Kaposi|HIV Infections | | PHASE3 |
| NCT04423926 | The First Affiliated Hospital with Nanjing Medical University | PTCL, NOS|AITL|ALK- ALCL|Phase III-IV ALK&addition; ALCL|EATL | 2020-06-10 | PHASE1|PHASE2 |
| NCT00507962 | M.D. Anderson Cancer Center | Advanced Cancer | 2005-03 | PHASE1 |
| NCT01088724 | A.O. Ospedale Papa Giovanni XXIII | Post-transplant Lymphoproliferative Disease (PTLD)|Non Burkitt | 2002-02 | PHASE4 |
| NCT00006235 | Gynecologic Oncology Group|National Cancer Institute (NCI) | Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer | | PHASE1 |
| NCT00003389 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) | Lymphoma | 1999-06-17 | PHASE3 |
| NCT02131480 | Gustave Roussy, Cancer Campus, Grand Paris | Uterus Leiomyosarcoma|Soft Tissue Leiomyosarcoma | 2010-06 | PHASE2 |
| NCT00400946 | Dana-Farber Cancer Institute|National Cancer Institute (NCI) | Drug+Agent Toxicity by Tissue+Organ|Leukemia | 2005-04 | PHASE3 |
| NCT00635726 | Hellenic Oncology Research Group|University Hospital of Crete | Bladder Cancer | 2008-02 | PHASE2 |
| NCT01202890 | New Mexico Cancer Research Alliance|Celgene Corporation | Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma | 2010-09 | PHASE1 |
| NCT02359162 | Sun Yat-sen University | Lymphoma, Extranodal NK-T-Cell | 2015-05 | PHASE3 |
| NCT00102973 | Telik | Ovarian Neoplasms | 2004-12 | PHASE3 |
| NCT04077905 | Beijing Friendship Hospital | Hemophagocytic Lymphohistiocytosis | 2019-08-31 | PHASE3 |
| NCT03817853 | Hoffmann-La Roche | Advanced Follicular Lymphoma | 2019-02-26 | PHASE4 |
| NCT00058422 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) | Lymphoma | 2003-02-10 | PHASE2 |
| NCT00780039 | Merck Sharp & Dohme LLC|Princess Margaret Hospital, Canada | Ovarian Neoplasms | 2003-10-01 | PHASE2 |
| NCT05270057 | Medical College of Wisconsin | B-cell Lymphoma|Burkitt Lymphoma | 2023-01-26 | PHASE1 |
| NCT03539328 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Ovarian Cancer | 2018-06 | PHASE2 |
| NCT03596281 | Gustave Roussy, Cancer Campus, Grand Paris | Ovarian Cancer | 2018-12-05 | PHASE1 |
| NCT00102219 | Eli Lilly and Company | Breast Cancer | 2004-10 | PHASE2 |
| NCT07278856 | City of Hope Medical Center|National Cancer Institute (NCI) | Follicular Helper T-Cell Lymphoma|Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type|Follicular Helper T-Cell Lymphoma, Follicular-Type|Follicular Helper T-Cell Lymphoma, Not Otherwise Specified|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified | 2026-04-27 | PHASE1 |
| NCT00004237 | Royal Marsden NHS Foundation Trust | Breast Cancer | 1998-10 | PHASE2 |
| NCT00976131 | Columbia University | Breast Cancer | 2009-09 | PHASE1 |
| NCT00822120 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Lymphoma|Nonneoplastic Condition | 2009-07 | PHASE2 |
| NCT01593020 | M.D. Anderson Cancer Center|Eisai Inc. | Breast Cancer | 2012-08-03 | PHASE2 |
| NCT04213794 | Mayo Clinic | Malignant Abdominal Neoplasm|Malignant Pelvic Neoplasm|Recurrent Colon Carcinoma|Recurrent Desmoplastic Small Round Cell Tumor|Recurrent Fallopian Tube Carcinoma|Recurrent Gastric Carcinoma|Recurrent Liposarcoma|Recurrent Malignant Mesothelioma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Rectal Carcinoma|Recurrent Rhabdomyosarcoma|Recurrent Sarcoma|Refractory Colon Carcinoma|Refractory Desmoplastic Small Round Cell Tumor|Refractory Fallopian Tube Carcinoma|Refractory Gastric Carcinoma|Refractory Liposarcoma|Refractory Malignant Mesothelioma|Refractory Ovarian Carcinoma|Refractory Primary Peritoneal Carcinoma|Refractory Rectal Carcinoma|Refractory Rhabdomyosarcoma|Refractory Sarcoma|Resectable Liposarcoma|Resectable Malignant Mesothelioma|Resectable Sarcoma | 2019-11-08 | EARLY_PHASE1 |
| NCT05913427 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | Adrenocortical Carcinoma | 2022-06-08 | PHASE2 |
| NCT00005861 | Gynecologic Oncology Group|National Cancer Institute (NCI) | Endometrial Cancer | 2000-05 | PHASE2 |
| NCT01779050 | Washington University School of Medicine|Genentech, Inc. | Breast Neoplasms | 2013-12-19 | PHASE2 |
| NCT05177796 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Breast Inflammatory Carcinoma|Invasive Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma | 2022-03-11 | PHASE2 |
| NCT03023046 | University of Washington|National Cancer Institute (NCI) | Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma | 2017-02-23 | PHASE2 |
| NCT00376961 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Lymphoma | 2006-08 | PHASE2 |
| NCT00128778 | Spanish Breast Cancer Research Group|Schering-Plough | Breast Neoplasms | 2002-10-28 | PHASE4 |
| NCT01321008 | M.D. Anderson Cancer Center | Lymphoma | 2011-05 | PHASE1|PHASE2 |
| NCT01468740 | Harlachinger Krebshilfe e.V.|Deutsche AIDS Gesellschaft e.V. | HIV-associated Hodgkin Lymphoma | 2004-03 | PHASE2 |
| NCT01027910 | Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Pharmacyclics LLC. | Sarcoma | 2009-02 | PHASE1|PHASE2 |
| NCT02779283 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) | Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia | 2016-01-13 | PHASE1 |
| NCT00740805 | National Cancer Institute (NCI) | Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma|Solid Neoplasm | 2008-08-18 | PHASE1 |
| NCT06023862 | Yonsei University|GlaxoSmithKline | Ovarian Neoplasms|Endometrial Neoplasms|Uterine Cervical Neoplasms|Vulvar Cancer|Vagina Neoplasm|Clear Cell Carcinoma | 2024-01-22 | PHASE2 |
| NCT01095926 | University Hospital Muenster | Wilms Tumor|Neuroblastoma|Soft Tissue Sarcoma|Acute Lymphoblastic Leukemia | 2010-05 | PHASE2 |
| NCT00002489 | Memorial Sloan Kettering Cancer Center | Extragonadal Germ Cell Tumor|Ovarian Cancer | 1991-10 | PHASE2 |
| NCT02414568 | The Lymphoma Academic Research Organisation | Classical Hodgkin Lymphoma | 2015-07-17 | PHASE2 |
| NCT00002641 | European Organisation for Research and Treatment of Cancer - EORTC|NCIC Clinical Trials Group | Endometrial Cancer|Kidney Cancer|Ovarian Cancer|Pheochromocytoma|Sarcoma | 1995-02 | PHASE3 |
| NCT01659554 | Columbia University | Recurrent Ovarian Cancer|Fallopian Tube Cancer | 2012-03 | PHASE2 |
| NCT00671476 | Dr. Susan Love Research Foundation | Breast Cancer | 2008-02 | NA |
| NCT03248427 | SOLTI Breast Cancer Research Group|Novartis | Breast Cancer | 2017-07-13 | PHASE2 |
| NCT02855359 | Seagen Inc. | Diffuse, Large B-Cell, Lymphoma|Follicular Lymphoma, Grade 3b|Transformed Lymphoma + DLBCL | 2016-08 | PHASE2 |
| NCT01228331 | Universit?tsklinikum Hamburg-Eppendorf | Leukemia | 2010-10 | PHASE2|PHASE3 |
| NCT03587662 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Metastatic Kidney Medullary Carcinoma|Metastatic Renal Cell Carcinoma|SMARCB1 Negative|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8 | 2018-08-17 | PHASE2 |
| NCT02636322 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Diffuse Large B-Cell Lymphoma Unclassifiable | 2016-03-29 | PHASE2 |
| NCT00082095 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA | Metastatic Breast Cancer | 2004-04 | PHASE3 |
| NCT00002601 | City of Hope Medical Center|National Cancer Institute (NCI) | Sarcoma | 1994-09 | PHASE2 |
| NCT06425302 | Celgene | Lymphoma, Follicular | 2024-08-30 | PHASE2 |
| NCT03712202 | City of Hope Medical Center|National Cancer Institute (NCI) | Ann Arbor Stage I Hodgkin Lymphoma|Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma|Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma|Ann Arbor Stage IA Hodgkin Lymphoma|Ann Arbor Stage IB Hodgkin Lymphoma|Ann Arbor Stage II Hodgkin Lymphoma|Ann Arbor Stage IIA Hodgkin Lymphoma|Ann Arbor Stage IIB Hodgkin Lymphoma|Classic Hodgkin Lymphoma|Lymphocyte-Rich Classic Hodgkin Lymphoma|Ann Arbor Stage I Lymphocyte-Depleted Classic HL|Ann Arbor Stage II Lymphocyte-Depleted Classic HL|Ann Arbor Stage II Mixed Cellularity Classic HL|Ann Arbor Stage II Nodular Sclerosis Classic HL | 2018-11-28 | PHASE2 |
| NCT00002822 | Medical Research Council | Lung Cancer | 1996-03 | PHASE3 |
| NCT00147875 | University of Cologne|German Hodgkin´s Lymphoma Study Group|Eli Lilly and Company | Hodgkin´s Disease | 2004-03 | PHASE1|PHASE2 |
| NCT06268457 | Istituto Ortopedico Rizzoli | Desmoid | 2024-02-20 | |
| NCT00001165 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Islet Cell Adenoma|Neoplasm Metastasis|Zollinger Ellison Syndrome | 1978-09 | PHASE2 |
| NCT00030472 | Gynecologic Oncology Group|National Cancer Institute (NCI) | Cervical Cancer | 2001-12 | PHASE2 |
| NCT00002539 | European Organisation for Research and Treatment of Cancer - EORTC|Medical Research Council | Sarcoma | 1993-08 | PHASE3 |
| NCT00484601 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Refractory Nasopharyngeal Carcinoma | 2004-04-15 | PHASE2 |
| NCT02446600 | National Cancer Institute (NCI)|AstraZeneca|NRG Oncology | Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Tumor|Ovarian Seromucinous Carcinoma|Ovarian Serous Tumor|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Ovarian Endometrioid Adenocarcinoma|Recurrent Primary Peritoneal Carcinoma | 2016-03-28 | PHASE3 |
| NCT02584309 | Washington University School of Medicine | Sarcoma, Soft Tissue|Soft Tissue Sarcoma|Undifferentiated Pleomorphic Sarcoma|Leiomyosarcoma|Liposarcoma|Synovial Sarcoma|Myxofibrosarcoma|Angiosarcoma|Fibrosarcoma|Malignant Peripheral Nerve Sheath Tumor|Epithelioid Sarcoma | 2016-02-22 | PHASE2 |
| NCT05318794 | Imperial College London | Gastric Cancer|Peritoneal Metastases|Chemotherapy Effect | 2023-11 | PHASE2 |
| NCT07224100 | University of Washington|Takeda | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|B Lymphoblastic Leukemia+Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1|Lymphoblastic Lymphoma | 2026-03-30 | PHASE2 |
| NCT00002657 | SWOG Cancer Research Network|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group | Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm | 1995-05 | PHASE2 |
| NCT07044336 | AstraZeneca | Endometrial Cancer|Malignant Solid Tumour | 2025-08-01 | PHASE3 |
| NCT00801411 | National Cancer Centre, Singapore | Breast Cancer | 2008-10 | PHASE2 |
| NCT03971409 | Laura Huppert, MD, BA|Translational Breast Cancer Research Consortium|Hoosier Cancer Research Network|Array BioPharma|Pfizer|Breast Cancer Research Foundation|Johns Hopkins University|Gilead Sciences | Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Invasive Breast Carcinoma|Recurrent Breast Carcinoma|Triple-Negative Breast Carcinoma|Unresectable Breast Carcinoma | 2019-07-08 | PHASE2 |
| NCT02734771 | Patrick Reagan|Seagen Inc. | Diffuse Large B-Cell Lymphoma | 2016-06 | PHASE2 |
| NCT02293109 | Mehrdad Abedi, MD|Amgen | Contiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia | 2015-12-17 | PHASE1 |
| NCT00217425 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) | Lymphoma | 2006-09-14 | PHASE2 |
| NCT02670616 | Samsung Medical Center | Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma | 2016-05-01 | PHASE2 |
| NCT00003052 | European Organisation for Research and Treatment of Cancer - EORTC|The European Society for Hyperthermic Oncology | Sarcoma | 1997-07 | PHASE3 |
| NCT02531308 | Rush University Medical Center | Diffuse Large B-Cell Lymphoma | 2015-07 | PHASE2 |
| NCT00144807 | Lymphoma Study Association | Diffuse Large Cell Lymphoma | 2003-12 | PHASE2 |
| NCT05661201 | Georgetown University|Immune System Key Ltd | Solid Tumor|KRAS Mutation-Related Tumors | 2023-04-12 | PHASE1 |
| NCT01492881 | UNC Lineberger Comprehensive Cancer Center|Merck Sharp & Dohme LLC | Multiple Myeloma | 2012-04 | PHASE2 |
| NCT06394492 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Ovarian Cancer | 2024-05-10 | PHASE3 |
| NCT03299036 | National Cheng-Kung University Hospital|The Industrial Technology Research Institute|National Cheng Kung University | Cancer of Liver | 2017-06-01 | NA |
| NCT00162721 | Gustave Roussy, Cancer Campus, Grand Paris | Uterine Sarcoma | 2001-09 | PHASE3 |
| NCT00654732 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Classic Hodgkin Lymphoma|Lugano Classification Stage III Hodgkin Lymphoma AJCC v8|Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8 | 2008-03-19 | PHASE2 |
| NCT00484432 | AGC Biologics S.p.A. | Ovarian Cancer Metastatic Recurrent | 2008-11 | PHASE2 |
| NCT04685616 | University College, London|Takeda|University of Miami|European Organisation for Research and Treatment of Cancer - EORTC|Australasian Leukaemia and Lymphoma Group|Seagen Inc.|Canadian Cancer Trials Group | Hodgkin Lymphoma | 2022-04-14 | PHASE3 |
| NCT03036904 | Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center | Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma | 2017-02-06 | PHASE1 |
| NCT05354076 | Fudan University | Advanced Malignant Tumors | 2000-03-01 | PHASE2 |
| NCT05137262 | M.D. Anderson Cancer Center|AstraZeneca | Urothelial Carcinoma|Bladder Cancer | 2021-10-13 | PHASE2 |
| NCT01964391 | Hoffmann-La Roche | Breast Cancer | 2014-02-21 | PHASE3 |
| NCT00501826 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma | 2007-07-11 | PHASE2 |
| NCT00115414 | Amgen | Breast Cancer|Fever|Neutropenia | | PHASE2 |
| NCT00651755 | M.D. Anderson Cancer Center|Merck Sharp & Dohme LLC | Lymphoma | 2008-03 | NA |
| NCT06340568 | BioNTech SE|DualityBio Inc.|BioNTech (Shanghai) Pharmaceuticals Co., Ltd. | Endometrial Cancer | 2025-06-10 | PHASE3 |
| NCT00005959 | Amgen | Lymphoma | 1999-12 | PHASE2 |
| NCT07258680 | N.N. Petrov National Medical Research Center of Oncology | Peripheral T-cell Lymphoma | 2013-10 | PHASE3 |
| NCT06250959 | Chen Suning | ALL, Adult|Philadelphia-Negative ALL | 2024-02-05 | PHASE2 |
| NCT00312650 | Women and Infants Hospital of Rhode Island|Ortho Biotech, Inc. | Ovarian Carcinoma | 2006-04 | PHASE2 |
| NCT04626791 | Academic and Community Cancer Research United|National Cancer Institute (NCI) | Mantle Cell Lymphoma | 2021-08-03 | PHASE2 |
| NCT00002610 | Children´s Oncology Group|National Cancer Institute (NCI) | Kidney Cancer | 1996-01 | PHASE3 |
| NCT00004162 | University of Alabama at Birmingham|National Cancer Institute (NCI) | Lymphoma | 1997-06 | PHASE1 |
| NCT01516580 | Gustave Roussy, Cancer Campus, Grand Paris|Children´s Oncology Group | B-cell Non Hodgkin Lymphoma|Mature B-cell Leukemia Burkitt-type | 2011-12 | PHASE3 |
| NCT00002582 | Institute of Cancer Research, United Kingdom|Cancer Research Campaign Clinical Trials Centre|Scottish Cancer Therapy Network|Yorkshire Regional Clinical Trials Research Unit | Breast Cancer | 1993-06 | PHASE3 |
| NCT02889523 | The Lymphoma Academic Research Organisation|Epizyme, Inc. | Lymphoma|DLBCL|Follicular Lymphoma | 2016-10 | PHASE1|PHASE2 |
| NCT01966471 | Hoffmann-La Roche | Breast Cancer | 2014-01-31 | PHASE3 |
| NCT01258634 | University of Chicago | Osteosarcoma|Lung Metastases | 2010-07 | PHASE1 |
| NCT01390584 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI) | Lymphoma | 2013-05-24 | PHASE2 |
| NCT04032964 | Philogen S.p.A. | Soft Tissue Sarcoma | 2019-09-05 | PHASE1 |
| NCT07097363 | University of Washington|AbbVie | B-Cell Non-Hodgkin Lymphoma|Burkitt Lymphoma|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Primary Mediastinal Large B-Cell Lymphoma|T-Cell+Histiocyte-Rich Large B-Cell Lymphoma|Transformed B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma to Diffuse Large B-Ce | 2025-12-07 | PHASE2 |
| NCT01281514 | Fox Chase Cancer Center | Fallopian Tube Cancer|Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer | 2010-12-14 | PHASE1 |
| NCT00003133 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) | Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter | 1997-09 | PHASE1 |
| NCT01851733 | Washington University School of Medicine|The Foundation for Barnes-Jewish Hospital | Glioblastoma | 2013-08-13 | PHASE1 |
| NCT00002714 | Stanford University|National Cancer Institute (NCI) | Lymphoma | 1995-04 | PHASE2 |
| NCT00002803 | Children´s Hospital Medical Center, Cincinnati | Neuroblastoma | 1995-07 | PHASE2 |
| NCT06984146 | National Medical Research Radiological Centre of the Ministry of Health of Russia | Hodgkin Lymphoma, Adult | 2025-04-15 | PHASE2 |
| NCT02306161 | National Cancer Institute (NCI) | Metastatic Ewing Sarcoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Malignant Neoplasm in the Bone Marrow|Metastatic Malignant Neoplasm in the Lung|Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone|Peripheral Primitive Neuroectodermal Tumor of Soft Tissues | 2014-12-12 | PHASE3 |
| NCT02379585 | Western Regional Medical Center | HER2-positive Breast Cancer | 2013-01 | PHASE1|PHASE2 |
| NCT00003896 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer | 1999-09 | PHASE2 |
| NCT00379457 | European Paediatric Soft Tissue Sarcoma Study Group|Italian Association for Pediatric Hematology Oncology|Children´s Cancer and Leukaemia Group|Dutch Childhood Oncology Group | Sarcoma | 2006-06 | PHASE3 |
| NCT01275677 | National Cancer Institute (NCI)|NRG Oncology | HER2+Neu Positive|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7 | 2011-02-08 | PHASE3 |
| NCT01775475 | AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC|University of Arkansas | AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Lymphoblastic Lymphoma|AIDS-related Peripheral+Systemic Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma|Stage III AIDS-related Lymphoma|Stage IV AIDS-related Lymphoma | 2016-09-15 | PHASE2 |
| NCT05561036 | Sun Yat-sen University | Desmoid Tumor | 2020-09-29 | PHASE3 |
| NCT00016172 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) | Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific | 2000-11 | PHASE1 |
| NCT03994107 | Peking Union Medical College|CSPC Ouyi Pharmaceutical Co., Ltd. | Breast Cancer | 2019-10-01 | PHASE1|PHASE2 |
| NCT03853044 | Ruijin Hospital | Angioimmunoblastic T-cell Lymphoma | 2018-12-29 | PHASE2 |
| NCT00136435 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Massachusetts General Hospital|Queen Elizabeth II Health Sciences Centre | Acute Lymphoblastic Leukemia | 2002-06 | PHASE2 |
| NCT00363090 | Toronto Sunnybrook Regional Cancer Centre | Lymphoma | 2006-09 | PHASE1|PHASE2 |
| NCT01230983 | Children´s Oncology Group|National Cancer Institute (NCI) | Cardiac Toxicity|Leukemia|Lymphoma | 1996-06 | PHASE3 |
| NCT02822157 | Universitaire Ziekenhuizen KU Leuven|AstraZeneca | Ovarian Epithelial Cancer | 2016-08 | PHASE2 |
| NCT05200312 | The First Affiliated Hospital with Nanjing Medical University | Non Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma | 2022-02-01 | PHASE2 |
| NCT00956930 | Northwestern University|National Cancer Institute (NCI) | Liver Cancer | 2009-08 | PHASE2 |
| NCT04623541 | Genmab|AbbVie|Eli Lilly and Company | Relapsed+Refractory Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Richter´s Syndrome|Treatment-na?ve High Risk Chronic Lymphocytic Leukemia | 2020-11-25 | PHASE1|PHASE2 |
| NCT00002905 | Centro di Riferimento Oncologico - Aviano | Lymphoma | 1995-06 | PHASE2 |
| NCT00025441 | Societe Internationale d´Oncologie Pediatrique|Children´s Cancer and Leukaemia Group|Societe Francaise Oncologie Pediatrique | Ovarian Cancer|Sarcoma|Small Intestine Cancer | 1998-11 | PHASE2 |
| NCT01100372 | Medical University Innsbruck | Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer | 2009-07 | PHASE2 |
| NCT00669877 | M.D. Anderson Cancer Center | Burkitt´s Lymphoma|Burkitt´S-like Lymphoma | 2002-08 | PHASE2 |
| NCT01702129 | University Hospital, Basel, Switzerland | Solid Tumors | 2007-01 | PHASE1 |
| NCT00000801 | National Institute of Allergy and Infectious Diseases (NIAID) | Lymphoma, Non-Hodgkin|HIV Infections | | PHASE2 |
| NCT00983944 | Ohio State University Comprehensive Cancer Center | Lymphoma | 2009-09 | PHASE2 |
| NCT02811523 | University Health Network, Toronto | Bone Sarcoma|Soft Tissue Sarcoma|Pulmonary Metastases | 2016-02 | PHASE1 |
| NCT00003296 | Brown University | Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Liver Cancer | 1998-01 | PHASE2 |
| NCT00525642 | Fudan University | Breast Neoplasms|Adjuvant|Chemotherapy | 2003-06 | PHASE2|PHASE3 |
| NCT00225173 | Stanford University|National Cancer Institute (NCI) | Hodgkin Disease | 2001-10 | PHASE2 |
| NCT03036488 | Merck Sharp & Dohme LLC | Triple Negative Breast Neoplasms | 2017-03-07 | PHASE3 |
| NCT00038142 | M.D. Anderson Cancer Center | Ewing´s Sarcoma | 1997-11 | PHASE2 |
| NCT04516447 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Solid Tumor|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer | 2020-10-26 | PHASE1 |
| NCT01005758 | Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI) | Leukemia | 2009-01 | PHASE2 |
| NCT05483933 | Shattuck Labs, Inc. | Platinum-resistant Ovarian Cancer|Fallopian Tube Cancer|Epithelial Ovarian Cancer|Ovarian Cancer|Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Primary Peritoneal Carcinoma|Primary Peritoneal Carcinoma | 2022-08-18 | PHASE1 |
| NCT03360760 | Peking University People´s Hospital | Osteosarcoma of Pelvis | 2018-08-01 | NA |
| NCT00365274 | National Cancer Institute (NCI) | Anaplastic Large Cell Lymphoma | 2006-08 | PHASE2 |
| NCT06172296 | National Cancer Institute (NCI) | Ganglioneuroblastoma, Nodular|Neuroblastoma | 2024-04-19 | PHASE3 |
| NCT01148446 | Fondazione Italiana Linfomi - ETS | Elderly Patients (>65 Years)|Diffuse Large B Cell Lymphoma (DLBCL) | 2003-01 | PHASE3 |
| NCT06251180 | Guangzhou Lupeng Pharmaceutical Company LTD. | B-cell Non-Hodgkin Lymphoma | 2024-04-10 | PHASE1 |
| NCT05600686 | Joseph Tuscano|National Cancer Institute (NCI)|ADC Therapeutics S.A. | Double-Expressor Lymphoma|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | 2023-05-24 | PHASE2 |
| NCT00567567 | Children´s Oncology Group|National Cancer Institute (NCI) | Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Recurrent Neuroblastoma|Regional Neuroblastoma|Stage 4 Neuroblastoma|Stage 4S Neuroblastoma | 2007-11-05 | PHASE3 |
| NCT00003907 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) | Liver Cancer|Metastatic Cancer | 1999-12-15 | PHASE2 |
| NCT04021992 | Sun Yat-sen University | Lymphoma, Large B-Cell, Diffuse | 2019-07-15 | PHASE2 |
| NCT00041119 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Breast Cancer | 2002-05 | PHASE3 |
| NCT01516567 | Gustave Roussy, Cancer Campus, Grand Paris|Children´s Oncology Group | Primary Mediastinal Large B Cell Lymphoma | 2012-04-01 | PHASE2 |
| NCT02631109 | Beijing Friendship Hospital | Hemophagocytic Lymphohistiocytosis | 2015-12 | PHASE3 |
| NCT00006016 | National Cancer Institute (NCI) | Adult Primary Hepatocellular Carcinoma|Advanced Adult Primary Liver Cancer|Localized Unresectable Adult Primary Liver Cancer | 2000-05 | PHASE2 |
| NCT00477412 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Mantle Cell Lymphoma | 2007-04-03 | PHASE1|PHASE2 |
| NCT04101812 | Tianjin Medical University Second Hospital|CSPC Pharmaceutical Group Limited | Muscle Invasive Bladder Cancer | 2019-09-17 | PHASE2 |
| NCT00002557 | National Cancer Institute (NCI) | Lymphoma | 1993-06 | PHASE2 |
| NCT02180867 | National Cancer Institute (NCI) | Alveolar Soft Part Sarcoma|Angiomatoid Fibrous Histiocytoma|Atypical Fibroxanthoma|Clear Cell Sarcoma of Soft Tissue|Epithelioid Malignant Peripheral Nerve Sheath Tumor|Epithelioid Sarcoma|Extraskeletal Myxoid Chondrosarcoma|Extraskeletal Osteosarcoma|Fibrohistiocytic Neoplasm|Fibrosarcoma|Inflammatory Myofibroblastic Tumor|Intimal Sarcoma|Leiomyosarcoma|Liposarcoma|Liver Embryonal Sarcoma|Low Grade Fibromyxoid Sarcoma|Low Grade Myofibroblastic Sarcoma|Malignant Peripheral Nerve Sheath Tumor|Malignant Skin Granular Cell Tumor|Malignant Triton Tumor|Mesenchymal Chondrosarcoma|Myxofibrosarcoma|Myxoid Chondrosarcoma|Myxoinflammatory Fibroblastic Sarcoma|Nerve Sheath Neoplasm|PEComa|Pericytic Neoplasm|Plexiform Fibrohistiocytic Tumor|Sclerosing Epithelioid Fibrosarcoma|Skin Glomus Tumor|Stage IB Soft Tissue Sarcoma AJCC v7|Stage IIB Soft Tissue Sarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Synovial Sarcoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone | 2014-07-11 | PHASE2|PHASE3 |
| NCT04799275 | National Cancer Institute (NCI) | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Grade 3b Follicular Lymphoma|HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Intravascular Large B-Cell Lymphoma|Lymphoplasmacytic Lymphoma|Nodular Lymphocyte Predominant B-Cell Lymphoma|Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|T-Cell+Histiocyte-Rich Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma | 2021-05-20 | PHASE2|PHASE3 |
| NCT05453500 | University of Washington|Incyte Corporation | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 2023-03-27 | PHASE2 |
| NCT03497702 | National Cancer Center, Korea | Breast Cancer|Invasive Breast Cancer | 2017-05-08 | PHASE2 |
| NCT00002812 | Children´s Oncology Group|National Cancer Institute (NCI) | Leukemia | 1996-09 | PHASE3 |
| NCT05959720 | Instituto do Cancer do Estado de S?o Paulo|Servier | Acute Lymphoid Leukemia|Minimal Residual Disease|Gene Abnormality|Chemotherapeutic Toxicity | 2023-09-05 | |
| NCT00060385 | European Organisation for Research and Treatment of Cancer - EORTC | Lymphoma | 2003-03 | PHASE2|PHASE3 |
| NCT02181738 | Bristol-Myers Squibb | Hodgkin Disease | 2014-08-12 | PHASE2 |
| NCT00667342 | St. Jude Children´s Research Hospital|Genentech, Inc. | Osteosarcoma|Malignant Fibrous Histiocytoma (MFH) of Bone | 2008-06-03 | PHASE2 |
| NCT05615623 | InSightec | Brain Tumor | 2023-01-04 | PHASE1|PHASE2 |
| NCT00107380 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Lymphoma | 2005-11 | PHASE2 |
| NCT05422066 | Li Zhiming|Antengene Corporation | DLBCL Germinal Center B-Cell Type | 2022-07-26 | PHASE2 |
| NCT00003050 | University of Southern California|National Cancer Institute (NCI) | Breast Cancer | 1997-04 | PHASE2 |
| NCT03726879 | Hoffmann-La Roche|Chugai Pharmaceutical | Breast Cancer | 2019-01-11 | PHASE3 |
| NCT00047229 | University Health Network, Toronto|National Cancer Institute (NCI) | Liver Cancer | 2002-10 | PHASE2 |
| NCT02285062 | Celgene | Lymphoma, Large B-Cell, Diffuse | 2015-02-17 | PHASE3 |
| NCT00887536 | NSABP Foundation Inc|Genentech, Inc.|US Oncology Research | Breast Cancer | 2009-05 | PHASE3 |
| NCT00002634 | Memorial Sloan Kettering Cancer Center | Neuroblastoma | 1995-02 | PHASE2 |
| NCT03018626 | Nanfang Hospital, Southern Medical University | Lymphoma, Large B-Cell, Diffuse | 2017-07-27 | PHASE3 |
| NCT00101101 | H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|Lymphoma Research Foundation|Novartis | Lymphoma | 2004-07 | PHASE2 |
| NCT00417053 | Children´s Cancer and Leukaemia Group | Neuroblastoma | | PHASE3 |
| NCT00187070 | St. Jude Children´s Research Hospital | Lymphoma, Large Cell|Lymphoma, Non-Hodgkin | 1997-12 | NA |
| NCT02475772 | Clemens Tempfer | Ovarian Cancer | 2016-11 | PHASE1 |
| NCT03514381 | Institut Claudius Regaud | Soft Tissue Sarcoma | 2018-05-18 | PHASE4 |
| NCT03220022 | National Cancer Institute (NCI) | AIDS-Related Lymphoma|Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | 2018-03-16 | PHASE1 |
| NCT00003437 | Medical Research Council | Leukemia | 1997-01 | PHASE3 |
| NCT02448537 | Massachusetts General Hospital|Dana-Farber Cancer Institute|PharmaMar | Metastatic Sarcoma | 2015-08 | PHASE2 |
| NCT02557854 | Theodore Laetsch | Rhabdomyosarcoma|Neuroblastoma|Sarcoma|Sarcoma, Ewing|Osteosarcoma|Desmoid | 2016-12 | PHASE1 |
| NCT00002757 | Children´s Oncology Group|National Cancer Institute (NCI)|Societe Francaise Oncologie Pediatrique|Children´s Cancer and Leukaemia Group | Leukemia|Lymphoma | 2001-06 | PHASE3 |
| NCT03742986 | NYU Langone Health | Breast Cancer | 2019-05-02 | PHASE2 |
| NCT00911183 | Institut Bergonié|National Cancer Institute, France | Lymphoma | 2008-12-02 | PHASE2 |
| NCT05411237 | AIDS Malignancy Consortium|National Cancer Institute (NCI) | Kaposi Sarcoma|HIV-1-infection|AIDS-related Kaposi Sarcoma | 2026-09 | PHASE3 |
| NCT00608803 | Alaunos Therapeutics | Advanced Cancer | 2008-01 | PHASE1 |
| NCT00003342 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) | Bladder Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter | 1997-12 | PHASE1 |
| NCT00123929 | Hospital San Carlos, Madrid|UNC Lineberger Comprehensive Cancer Center | Breast Cancer | 2005-01 | PHASE2 |
| NCT07551583 | M.D. Anderson Cancer Center | Hodgkin Lymphoma | 2026-10-01 | PHASE2 |
| NCT00324831 | Favrille | Lymphoma | | PHASE3 |
| NCT02606305 | ImmunoGen, Inc. | Epithelial Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer | 2016-03-02 | PHASE1|PHASE2 |
| NCT06742502 | Sun Yat-sen University | Primary Mediastinal Diffuse Large B-cell Lymphoma | 2024-11-12 | PHASE2 |
| NCT00016302 | National Cancer Institute (NCI) | T-cell Childhood Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia | 2001-04 | NA |
| NCT00856037 | University of Nebraska|National Cancer Institute (NCI) | Recurrent Small Cell Lung Carcinoma | 2009-02-02 | PHASE1 |
| NCT00146562 | Harold J. Burstein, MD, PhD|Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Lowell General Hospital|Brigham and Women´s Hospital|North Shore Medical Center | Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer | 2003-07 | PHASE2 |
| NCT00003388 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) | Lymphoma | 1999-07-26 | PHASE2 |
| NCT04203641 | Helix BioPharma Corporation|Theradex | Pancreas Cancer | 2019-12-11 | PHASE1|PHASE2 |
| NCT06911502 | Celgene | Follicular Lymphoma | 2025-07-28 | PHASE3 |
| NCT00182767 | National Cancer Institute (NCI) | Fallopian Tube Cancer|Female Reproductive Cancer|Recurrent Breast Cancer|Recurrent Ovarian Epithelial Cancer|Stage III Ovarian Epithelial Cancer|Stage IV Breast Cancer|Stage IV Ovarian Epithelial Cancer | 2006-01 | PHASE1|PHASE2 |
| NCT00005603 | Children´s Oncology Group|National Cancer Institute (NCI) | Leukemia | 2000-03 | PHASE3 |
| NCT00665457 | University of Nebraska|National Cancer Institute (NCI) | Breast Cancer | 2004-04-15 | PHASE2 |
| NCT03452553 | Boston Scientific Corporation|Biocompatabilities UK Ltd | Hepatocellular Carcinoma (HCC) | 2018-07-01 | NA |
| NCT00001337 | National Cancer Institute (NCI) | Diffuse Large B-Cell Lymphoma (DLBCL)|Primary Mediastinal Large B-cell Lymphoma|Burkitt Lymphoma|Anaplastic Large-Cell Lymphoma|Gray Zone Lymphoma | 1993-05-08 | PHASE2 |
| NCT00040872 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) | Neuroblastoma | 2000-06 | PHASE2 |
| NCT01078441 | National Cancer Institute (NCI) | Refractory Multiple Myeloma | 2010-09 | PHASE2 |
| NCT01946529 | St. Jude Children´s Research Hospital|University of Tennessee|University of Florida|Nemours Children´s Clinic | Desmoplastic Small Round Cell Tumor|Ewing Sarcoma of Bone or Soft Tissue|Localized Ewing Sarcoma+Peripheral Primitive Neuroectodermal Tumor|Metastatic Ewing Sarcoma+Peripheral Primitive Neuroectodermal Tumor | 2013-12-27 | PHASE2 |
| NCT00028886 | Commissie Voor Klinisch Toegepast Onderzoek | Multiple Myeloma and Plasma Cell Neoplasm | 2001-03 | PHASE3 |
| NCT01746173 | Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center | T-cell Non-Hodgkin Lymphoma | 2013-07 | PHASE2 |
| NCT02419469 | M.D. Anderson Cancer Center|Jazz Pharmaceuticals | Leukemia|Precursor-B Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Lymphoma | 2015-11-13 | PHASE2 |
| NCT01099436 | Borstkanker Onderzoek Groep|Dutch Cancer Society|Amgen|Sanofi|Novartis | Breast Cancer | 2010-04 | PHASE3 |
| NCT01294293 | Gynecologic Oncology Group|National Cancer Institute (NCI) | Malignant Ovarian Mixed Epithelial Tumor|Ovarian Brenner Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Ovarian Carcinoma | 2011-03 | PHASE1 |
| NCT03164993 | Oslo University Hospital|Hoffmann-La Roche|Norwegian Cancer Society|St. Olavs Hospital|Helse Stavanger HF|Rigshospitalet, Denmark|Vejle Hospital|NanoString Technologies, Inc.|Technical University of Denmark|Karolinska Institutet | Cancer, Breast|Triple Negative Breast Cancer | 2017-06-01 | PHASE2 |
| NCT00165087 | Dana-Farber Cancer Institute|Boston Children´s Hospital | Acute Lymphoblastic Leukemia | 1996-01 | PHASE3 |
| NCT01159236 | M.D. Anderson Cancer Center | Breast Cancer | 2010-09 | NA |
| NCT05899621 | Ruijin Hospital | Follicular Lymphoma | 2023-06-01 | |
| NCT00544167 | SCRI Development Innovations, LLC|Bayer | Breast Cancer | 2007-05 | NA |
| NCT00057811 | Children´s Oncology Group|National Cancer Institute (NCI) | Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Stage I Childhood Large Cell Lymphoma|Stage I Childhood Small Noncleaved Cell Lymphoma|Stage II Childhood Large Cell Lymphoma|Stage II Childhood Small Noncleaved Cell Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage III Childhood Small Noncleaved Cell Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Childhood Small Noncleaved Cell Lymphoma|Untreated Childhood Acute Lymphoblastic Leukemia | 2004-06 | PHASE2 |
| NCT06890884 | Merck Sharp & Dohme LLC | Lymphoma, Large B-Cell, Diffuse | 2025-04-11 | PHASE2 |
| NCT02916316 | Fondazione Italiana Linfomi - ETS | Lymphoma|Large B-Cell|Diffuse Large B-Cell | 2014-02-12 | |
| NCT04139304 | AIDS Malignancy Consortium|National Cancer Institute (NCI)|Janssen Scientific Affairs, LLC|Montefiore Medical Center|Memorial Sloan Kettering Cancer Center|AIDS and Cancer Specimen Resource|The Emmes Company, LLC | Plasmablastic Lymphoma|Ann Arbor Stage I Diffuse Large B-Cell Lymphoma|Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | 2021-05-24 | EARLY_PHASE1 |
| NCT04983550 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer | 2021-09 | PHASE2 |
| NCT00471965 | Sanofi | Carcinoma, Hepatocellular | 2007-03 | PHASE3 |
| NCT00049036 | National Cancer Institute (NCI) | AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Peripheral+Systemic Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma | 2003-03 | PHASE2 |
| NCT01040871 | Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Diffuse Large B-Cell Lymphoma | 2010-01 | PHASE2 |
| NCT00471484 | National Cancer Centre, Singapore | Liver Cancer | 2007-03 | PHASE2 |
| NCT03467178 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Recurrent, Platinum-resistant Ovarian Cancer | 2018-07-30 | PHASE2 |
| NCT06468943 | The First Affiliated Hospital of Soochow University | Effects of Chemotherapy|Safety Issues | 2023-07-01 | PHASE2 |
| NCT00006110 | UNC Lineberger Comprehensive Cancer Center | Breast Cancer | 1998-12 | PHASE2 |
| NCT00309920 | Heinrich-Heine University, Duesseldorf | Breast Cancer | 2004-01 | NA |
| NCT05929768 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Early Stage Triple-Negative Breast Carcinoma | 2023-09-15 | PHASE3 |
| NCT00617591 | H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation|Ortho Biotech Clinical Affairs, L.L.C. | Multiple Myeloma | 2008-01 | PHASE2 |
| NCT01796197 | Dana-Farber Cancer Institute | Breast Cancer | 2013-08 | PHASE2 |
| NCT04542824 | Genmab|AbbVie | Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma|Primary Mediastinal Large B Cell Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma | 2020-08-20 | PHASE1|PHASE2 |
| NCT03509246 | Seoul National University Hospital | Ovarian Neoplasm Epithelial|High Grade Serous Carcinoma | 2018-05-15 | PHASE2 |
| NCT03914625 | National Cancer Institute (NCI) | B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Down Syndrome | 2019-07-03 | PHASE3 |
| NCT00931918 | Millennium Pharmaceuticals, Inc. | Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) | 2009-10 | PHASE2 |
| NCT07486310 | Guangdong Provincial People´s Hospital | Advanced Gastric Cancer | 2026-03-01 | PHASE2 |
| NCT06791460 | Obstetrics & Gynecology Hospital of Fudan University | Ovarian Cancer Recurrent | 2025-03-18 | PHASE2|PHASE3 |
| NCT00000626 | National Institute of Allergy and Infectious Diseases (NIAID)|Amgen | HIV Infections|Hodgkin´s Disease | | PHASE2 |
| NCT00004218 | Leukemia Research Fund|Medical Research Council | Leukemia | 1999-10 | PHASE3 |
| NCT05138146 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Sarcoma, Soft Tissue | 2021-12-30 | PHASE2 |
| NCT00252889 | Christiana Care Health Services|Johnson & Johnson|GlaxoSmithKline | Small Cell Lung Cancer|Pancreatic Cancer|Head and Neck Cancer|Gastric Cancer|Esophageal Cancer | 2004-05 | PHASE1 |
| NCT01705691 | NSABP Foundation Inc|Eisai Inc. | Breast Cancer|HER2-negative Breast Cancer | 2012-09 | PHASE2 |
| NCT00003815 | Scotland and Newcastle Lymphoma Group | Lymphoma | 1994-06 | PHASE3 |
| NCT04884035 | Celgene | Lymphoma, B-Cell | 2021-09-15 | PHASE1 |
| NCT05645380 | University of Kansas Medical Center | Triple Negative Breast Cancer|Breast Cancer | 2022-12-05 | PHASE2 |
| NCT00081159 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Metastatic Cancer|Prostate Cancer | 2004-07 | PHASE2 |
| NCT00025428 | Societe Internationale d´Oncologie Pediatrique|Children´s Cancer and Leukaemia Group | Neuroblastoma | 2000-12 | PHASE3 |
| NCT00004236 | University of Leicester | Esophageal Cancer|Gastric Cancer | 1998-08 | PHASE2 |
| NCT01678664 | Federation Francophone de Cancerologie Digestive | Neuroendocrine Tumors|Hepatic Metastases|Metastases | 2012-12 | PHASE2 |
| NCT03517449 | Eisai Inc.|Merck Sharp & Dohme LLC | Endometrial Neoplasms | 2018-06-11 | PHASE3 |
| NCT03498716 | Hoffmann-La Roche|Breast International Group|Alliance Foundation Trials, LLC.|Jules Bordet Institute|Frontier Science & Technology Research Foundation, Inc. | Triple Negative Breast Cancer | 2018-08-02 | PHASE3 |
| NCT01569204 | University of Cologne | Hodgkin Lymphoma | 2012-10 | PHASE2 |
| NCT02641847 | Fudan University | Triple Negative Breast Cancer|Breast Cancer | 2016-01 | PHASE2|PHASE3 |
| NCT04443348 | Laura M. Spring, MD|Merck Sharp & Dohme LLC|Breast Cancer Research Foundation|Translational Breast Cancer Research Consortium | Triple Negative Breast Cancer|Hormone Receptor Positive (HR&addition;), HER2-negative Breast Cancer|Biopsy-proven, Positive Lymph Node(s) | 2020-12-16 | PHASE2 |
| NCT00002643 | National Cancer Institute (NCI)|Children´s Cancer Group | Neutropenia|Sarcoma | 1995-04 | PHASE2 |
| NCT06434064 | Roswell Park Cancer Institute | Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Unresectable Triple-Negative Breast Carcinoma|Metastatic Triple-Negative Breast Carcinoma | 2026-03-03 | PHASE2 |
| NCT04083963 | University of Illinois at Chicago | Triple Negative Breast Cancer | 2019-08-09 | PHASE2 |
| NCT00070447 | National Cancer Institute (NCI) | Lymphoma | 2003-11 | PHASE2 |
| NCT01818063 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University|Susan G. Komen Breast Cancer Foundation | Estrogen Receptor-negative Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-negative Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-negative Breast Cancer | 2013-04-25 | PHASE2 |
| NCT00808899 | St. Jude Children´s Research Hospital | Neuroblastoma | 2008-12 | PHASE2 |
| NCT01777152 | Seagen Inc.|Millennium Pharmaceuticals, Inc. | Anaplastic Large-Cell Lymphoma|Non-Hodgkin Lymphoma|T-Cell Lymphoma | 2013-01-31 | PHASE3 |
| NCT00000658 | National Institute of Allergy and Infectious Diseases (NIAID)|Schering-Plough | Lymphoma, Non-Hodgkin|HIV Infections | | PHASE3 |
| NCT00992706 | Swiss Cancer Institute | Breast Cancer|Palmar-plantar Erythrodysesthesia | 2009-09 | PHASE3 |
| NCT03681548 | Ayana Pharma Ltd.,|Lambda Therapeutic Research Ltd. | Ovarian Cancer Recurrent | 2018-08-29 | PHASE1 |
| NCT00972478 | National Cancer Institute (NCI) | Ann Arbor Stage II Non-Hodgkin Lymphoma|Ann Arbor Stage III Non-Hodgkin Lymphoma|Ann Arbor Stage IV Non-Hodgkin Lymphoma | 2010-11-15 | PHASE1|PHASE2 |
| NCT06584032 | Hutchmed | Advanced Endometrial Cancer | 2024-12-12 | PHASE3 |
| NCT00022945 | Corixa Corporation | Mantle Cell Lymphoma | | PHASE2 |
| NCT06239272 | St. Jude Children´s Research Hospital | Adipocytic Neoplasm|Liposarcoma|Atypical Fibroxanthoma|Angiomatoid Fibrous Histiocytoma|Myoepithelioma|Fibrosarcoma NOS|Myxofibrosarcoma|Angiosarcoma|Osteosarcoma, Extraskeletal | 2024-03-27 | PHASE1|PHASE2 |
| NCT01815294 | Janssen Research & Development, LLC | Neoplasms|Neoplasms, Ovarian|Neoplasms, Breast|Advanced or Refractory Solid Malignancies | 2013-05 | PHASE1 |
| NCT02758366 | Meyer Children´s Hospital IRCCS | Glioblastoma (GBM)|DIPG|Brainstem Glioma, Pediatric|Diffuse Spinal Glioma|Bilateral Thalamic Glioma|Gliomatosis Cerebri|Anaplastic Astrocytoma|Midline Diffuse Glioma | 2016-02 | PHASE2 |
| NCT07370506 | Tanta University | Breast Cancer|Doxorubicin Induced Cardiomyopathy | 2026-02 | PHASE1|PHASE2 |
| NCT00006184 | National Cancer Institute (NCI) | Multiple Myeloma | 2001-02-08 | PHASE2 |
| NCT00003086 | Louisiana State University Health Sciences Center Shreveport | Breast Cancer | 1997-03 | PHASE1|PHASE2 |
| NCT05457829 | Sun Yat-sen University|CSPC Ouyi Pharmaceutical Co., Ltd. | Rhabdomyosarcoma, Child | 2023-12-30 | PHASE2 |
| NCT00041132 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Lymphoma | 2002-09 | PHASE2 |
| NCT01882816 | Memorial Sloan Kettering Cancer Center | Thyroid Cancer | 2013-06-13 | PHASE2 |
| NCT01864109 | Memorial Sloan Kettering Cancer Center | Newly Diagnosed Ewing Sarcoma | 2013-05 | PHASE2 |
| NCT05949021 | Mridula George, MD | Triple Negative Breast Cancer (TNBC) | 2023-10-07 | PHASE2 |
| NCT00044993 | Introgen Therapeutics | Breast Cancer | 2002-02 | PHASE2 |
| NCT04739800 | National Cancer Institute (NCI)|NRG Oncology | Fallopian Tube Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Platinum-Refractory Fallopian Tube Carcinoma|Platinum-Refractory Ovarian Carcinoma|Platinum-Refractory Primary Peritoneal Carcinoma|Recurrent Fallopian Tube Clear Cell Adenocarcinoma|Recurrent Fallopian Tube Endometrioid Adenocarcinoma|Recurrent Fallopian Tube High Grade Serous Adenocarcinoma|Recurrent Fallopian Tube Mucinous Adenocarcinoma|Recurrent Fallopian Tube Transitional Cell Carcinoma|Recurrent Fallopian Tube Undifferentiated Carcinoma|Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma|Recurrent Ovarian Clear Cell Adenocarcinoma|Recurrent Ovarian Endometrioid Adenocarcinoma|Recurrent Ovarian High Grade Serous Adenocarcinoma|Recurrent Ovarian Low Grade Serous Adenocarcinoma|Recurrent Ovarian Mucinous Adenocarcinoma|Recurrent Ovarian Seromucinous Carcinoma|Recurrent Ovarian Transitional Cell Carcinoma|Recurrent Ovarian Undifferentiated Carcinoma|Recurrent Platinum-Resistant Fallopian Tube Carcinoma|Recurrent Platinum-Resistant Ovarian Carcinoma|Recurrent Platinum-Resistant Primary Peritoneal Carcinoma|Recurrent Primary Peritoneal Clear Cell Adenocarcinoma|Recurrent Primary Peritoneal Endometrioid Adenocarcinoma|Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma|Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma|Recurrent Primary Peritoneal Transitional Cell Carcinoma|Recurrent Primary Peritoneal Undifferentiated Carcinoma|Refractory Fallopian Tube Clear Cell Adenocarcinoma|Refractory Fallopian Tube Endometrioid Adenocarcinoma|Refractory Fallopian Tube High Grade Serous Adenocarcinoma|Refractory Fallopian Tube Mucinous Adenocarcinoma|Refractory Fallopian Tube Transitional Cell Carcinoma|Refractory Fallopian Tube Undifferentiated Carcinoma|Refractory Low Grade Fallopian Tube Serous Adenocarcinoma|Refractory Ovarian Clear Cell Adenocarcinoma|Refractory Ovarian Endometrioid Adenocarcinoma|Refractory Ovarian High Grade Serous Adenocarcinoma|Refractory Ovarian Low Grade Serous Adenocarcinoma|Refractory Ovarian Mucinous Adenocarcinoma|Refractory Ovarian Seromucinous Carcinoma|Refractory Ovarian Transitional Cell Carcinoma|Refractory Ovarian Undifferentiated Carcinoma|Refractory Primary Peritoneal Clear Cell Adenocarcinoma|Refractory Primary Peritoneal Endometrioid Adenocarcinoma|Refractory Primary Peritoneal High Grade Serous Adenocarcinoma|Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma|Refractory Primary Peritoneal Transitional Cell Carcinoma|Refractory Primary Peritoneal Undifferentiated Carcinoma | 2021-06-10 | PHASE2 |
| NCT00019864 | National Cancer Institute (NCI) | Cardiac Toxicity|Sarcoma | 2000-03 | PHASE2 |
| NCT02783599 | Eli Lilly and Company | Soft Tissue Sarcoma | 2016-10-11 | PHASE1 |
| NCT00266799 | Merck Sharp & Dohme LLC|Essex Pharma GmbH | Breast Cancer | 2006-01-13 | PHASE3 |
| NCT03792867 | National Cancer Centre, Singapore | Retroperitoneal Sarcoma | 2018-07-23 | NA |
| NCT00024167 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Prostate Cancer | 2002-04 | PHASE3 |
| NCT00877071 | University of Pittsburgh|Biocompatibles UK Ltd | Hepatocellular Carcinoma | 2008-11 | PHASE2 |
| NCT00561743 | Janssen-Ortho Inc., Canada | Multiple Myeloma | 2005-11 | PHASE2 |
| NCT01313884 | Stanford University|Amgen | Bone Cancer|Ewing´s Sarcoma | 2011-05 | PHASE2 |
| NCT07072585 | Children´s Oncology Group | Stage II T Lymphoblastic Leukemia+Lymphoma|Stage III T Lymphoblastic Leukemia+Lymphoma|Stage IV T Lymphoblastic Leukemia+Lymphoma|T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma | 2026-06-28 | PHASE2|PHASE3 |
| NCT04199026 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Metastatic Sarcoma|Recurrent Sarcoma|Resectable Sarcoma | 2025-02-25 | NA |
| NCT00538525 | King Faisal Specialist Hospital & Research Center | Breast Cancer | 2007-09 | NA |
| NCT06531447 | The National Center of Oncology, Azerbaijan | Breast Cancer | 2014-05 | PHASE2 |
| NCT01605526 | Hoffmann-La Roche | Sarcoma | 2012-05 | PHASE1 |
| NCT00365417 | NSABP Foundation Inc|Genentech, Inc.|Hoffmann-La Roche|International Drug Development Institute | Breast Cancer | 2006-08 | PHASE2 |
| NCT00061893 | Children´s Oncology Group|National Cancer Institute (NCI) | Sarcoma | 2004-04 | PHASE2 |
| NCT00002576 | Cancer Research Campaign Clinical Trials Centre | Lymphoma | 1992-11 | PHASE3 |
| NCT06765317 | Memorial Sloan Kettering Cancer Center|Genentech, Inc. | Diffuse Large B Cell Lymphoma (DLBCL)|High Grade B Cell Lymphoma | 2025-01-16 | PHASE2 |
| NCT00020449 | National Cancer Institute (NCI) | Sarcoma | 2001-01 | PHASE2 |
| NCT04432714 | The First Affiliated Hospital with Nanjing Medical University | DLBCL|Untreated|MYC Gene Rearrangement | 2020-06-09 | PHASE1|PHASE2 |
| NCT03101748 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Breast Inflammatory Carcinoma|Locally Advanced Breast Carcinoma|Metastatic Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7 | 2018-02-19 | PHASE1|PHASE2 |
| NCT00275106 | Children´s Cancer and Leukaemia Group|European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma | Lymphoma | 2004-09 | PHASE3 |
| NCT00562185 | University of Texas Southwestern Medical Center|Ortho Biotech Clinical Affairs, L.L.C. | Ovarian Cancer | 2008-05 | PHASE1|PHASE2 |
| NCT00436709 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) | Breast Cancer | 2006-07 | NA |
| NCT00001300 | National Cancer Institute (NCI) | Sarcoma | 1992-06 | PHASE3 |
| NCT04814875 | THERAPIM PTY LTD|Novotech (Australia) Pty Limited | Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|High Grade Serious or Endometrioid Carcinoma of the Ovary, Fallopian Tube, or Primary Peritoneal Cancer | 2021-09-01 | PHASE1|PHASE2 |
| NCT05774275 | Fudan University | High-Risk Localized Soft Tissue Sarcoma | 2022-08-25 | PHASE1|PHASE2 |
| NCT00194779 | University of Washington|National Cancer Institute (NCI) | Estrogen Receptor-negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Progesterone Receptor-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer | 2003-10 | PHASE2 |
| NCT07286266 | GlaxoSmithKline|European Network of Gynaecological Oncological Trial Groups (ENGOT)|GOG Foundation | Ovarian Neoplasms | 2026-06-24 | PHASE3 |
| NCT00018954 | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) | Leukemia|Lymphoma | 1992-10 | PHASE2 |
| NCT04660799 | Hoffmann-La Roche | Lymphoma, Large B-Cell, Diffuse | 2021-02-24 | PHASE2 |
| NCT04679064 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS|GlaxoSmithKline | Ovarian Cancer | 2020-12-01 | PHASE3 |
| NCT05275777 | National University Hospital, Singapore|Adagene Inc | HER2-negative Breast Cancer|Advanced Solid Tumor | 2022-05-19 | PHASE1|PHASE2 |
| NCT00002707 | NSABP Foundation Inc|National Cancer Institute (NCI) | Breast Cancer | 1995-12 | PHASE3 |
| NCT00450801 | University of Miami | Lymphoma | 2004-04 | PHASE2 |
| NCT05809830 | Grupo Espanol de Investigacion en Sarcomas | Advanced Soft-tissue Sarcoma | 2023-05-29 | PHASE1|PHASE2 |
| NCT00610792 | Millennium Pharmaceuticals, Inc. | Ovarian Cancer | 2006-07 | PHASE2 |
| NCT00002665 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Leukemia|Neutropenia|Thrombocytopenia | 1995-07 | PHASE2 |
| NCT03113500 | City of Hope Medical Center|National Cancer Institute (NCI) | Adult T-Cell Leukemia+Lymphoma|Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Angioimmunoblastic T-Cell Lymphoma|Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma|Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma|Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Hepatosplenic T-Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified | 2017-05-25 | PHASE2 |
| NCT00006261 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) | Breast Cancer | 2000-05 | PHASE2 |
| NCT01871766 | St. Jude Children´s Research Hospital | Rhabdomyosarcoma | 2013-12-04 | PHASE2 |
| NCT00632827 | University of California, San Francisco|Eisai Inc.|Washington University School of Medicine | Peripheral T-Cell Lymphoma | 2008-07-01 | PHASE2 |
| NCT06121570 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Neoplasms | 2023-11-01 | PHASE1 |
| NCT02839707 | National Cancer Institute (NCI)|NRG Oncology | Fallopian Tube High Grade Serous Adenocarcinoma|Ovarian High Grade Serous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Primary Peritoneal High Grade Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Fallopian Tube Clear Cell Adenocarcinoma|Recurrent Fallopian Tube Endometrioid Adenocarcinoma|Recurrent Fallopian Tube Undifferentiated Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Ovarian Clear Cell Adenocarcinoma|Recurrent Ovarian Endometrioid Adenocarcinoma|Recurrent Ovarian Undifferentiated Carcinoma|Recurrent Platinum-Resistant Fallopian Tube Carcinoma|Recurrent Platinum-Resistant Ovarian Carcinoma|Recurrent Platinum-Resistant Primary Peritoneal Carcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Primary Peritoneal Clear Cell Adenocarcinoma|Recurrent Primary Peritoneal Endometrioid Adenocarcinoma|Recurrent Primary Peritoneal Undifferentiated Carcinoma | 2017-06-23 | PHASE2|PHASE3 |
| NCT04329494 | City of Hope Medical Center|National Cancer Institute (NCI) | Clinical Stage IV Gastric Cancer AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVB Gastric Cancer AJCC v8|Malignant Uterine Neoplasm|Metastatic Appendix Carcinoma|Metastatic Colorectal Carcinoma|Metastatic Gastric Carcinoma|Metastatic Malignant Neoplasm in the Peritoneum|Metastatic Malignant Solid Neoplasm|Metastatic Ovarian Carcinoma|Pathologic Stage IV Gastric Cancer AJCC v8|Peritoneal Carcinomatosis|Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8|Stage IV Appendix Carcinoma AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Uterine Corpus Cancer AJCC v8|Stage IVA Appendix Carcinoma AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Uterine Corpus Cancer AJCC v8|Stage IVB Appendix Carcinoma AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Uterine Corpus Cancer AJCC v8|Stage IVC Appendix Carcinoma AJCC v8|Stage IVC Colorectal Cancer AJCC v8 | 2020-08-21 | PHASE1 |
| NCT00002494 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Leukemia|Lymphoma | 1992-05 | PHASE2 |
| NCT00003701 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) | Bladder Cancer|Urethral Cancer | 1999-04-02 | PHASE3 |
| NCT02853500 | Dana-Farber Cancer Institute | Liver Cancer | 2016-07 | PHASE4 |
| NCT00004030 | Georgetown University|National Cancer Institute (NCI) | Unspecified Adult Solid Tumor, Protocol Specific | 1996-03 | PHASE1|PHASE2 |
| NCT01746238 | Massachusetts General Hospital | Sarcoma | 2013-03 | PHASE1 |
| NCT00005980 | European Organisation for Research and Treatment of Cancer - EORTC | Breast Cancer | 2000-04 | PHASE2 |
| NCT00002618 | Children´s Oncology Group|National Cancer Institute (NCI) | Lymphoma | 1994-12 | PHASE3 |
| NCT00043979 | National Cancer Institute (NCI) | Sarcoma | 2002-09-19 | PHASE2 |
| NCT00193115 | SCRI Development Innovations, LLC|Aventis Pharmaceuticals | Breast Cancer | 2004-03 | PHASE2 |
| NCT05371093 | Kite, A Gilead Company | Relapsed+Refractory Follicular Lymphoma | 2022-09-22 | PHASE3 |
| NCT00007904 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) | Breast Cancer | 2000-07 | PHASE2 |
| NCT00526318 | German Society for Pediatric Oncology and Hematology GPOH gGmbH | Neuroblastoma | 2007-01 | NA |
| NCT02733380 | Henan Cancer Hospital | Diffuse Large B-cell Lymphoma | 2016-05 | PHASE2 |
| NCT02420717 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Recurrent B Acute Lymphoblastic Leukemia|Recurrent Ph-Like Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory Ph-Like Acute Lymphoblastic Leukemia | 2015-07-15 | PHASE2 |
| NCT00023868 | American College of Radiology Imaging Network|National Cancer Institute (NCI) | Colorectal Cancer|Metastatic Cancer | 2001-11-01 | PHASE3 |
| NCT01940497 | Hoffmann-La Roche | Breast Cancer | 2013-11-15 | PHASE3 |
| NCT00451178 | Eli Lilly and Company | Lymphoma | 2007-05 | PHASE2 |
| NCT03758989 | University of Rochester | DLBCL | 2019-05-08 | PHASE2 |
| NCT00025649 | European Infant Neuroblastoma Study Group - 1999 | Neuroblastoma | 1999-07 | PHASE2 |
| NCT03017326 | University of Birmingham|Fundació Institut Germans Trias i Pujol|University Hospital Munich|University Hospital, Bonn|University of Kiel|University Hospital Tuebingen|University of Padova|Ludwig-Maximilians - University of Munich|Medical University of Gdansk|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Motol University Hospital|Rennes University Hospital|Children´s University Hospital, Ireland|University of Oslo|Princess Maxima Center for Pediatric Oncology|Andaluz Health Service|Swiss Pediatric Oncology Group|Gothia Forum - Center for Clinical Trial|The Leeds Teaching Hospitals NHS Trust|Bambino Gesù Hospital and Research Institute|Newcastle University|Experimental Cancer Medicine Centres|XenTech, Evry | Hepatoblastoma|Carcinoma, Hepatocellular | 2017-08-24 | PHASE3 |
| NCT00883116 | R-Pharm | Endometrial Cancer | 2009-08 | PHASE3 |
| NCT00401804 | Austrian Forum Against Cancer | Multiple Myeloma|Renal Insuficiency | 2006-02 | PHASE2 |
| NCT00077428 | National Cancer Institute (NCI)|SWOG Cancer Research Network | Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Salivary Gland Cancer|Salivary Gland Adenoid Cystic Carcinoma|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Salivary Gland Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Salivary Gland Cancer | 2004-06 | PHASE2 |
| NCT00416377 | Children´s Cancer and Leukaemia Group | Lymphoma | | NA |
| NCT01363128 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Acute Lymphoblastic Leukemia|Adult Acute Lymphoblastic Leukemia in Complete Remission|Burkitt Leukemia|Burkitt Lymphoma|CD20 Positive|Childhood Acute Lymphoblastic Leukemia in Complete Remission|Lymphoblastic Lymphoma | 2011-07-12 | PHASE2 |
| NCT03108300 | Ain Shams University | Malignant Soft Tissue Sarcoma | 2019-08-30 | PHASE2 |
| NCT01659099 | The Lymphoma Academic Research Organisation|Hoffmann-La Roche | Diffuse Large B Cell Lymphoma CD20 Positive | 2012-09 | PHASE3 |
| NCT03023358 | Nanfang Hospital, Southern Medical University | Peripheral T Cell Lymphoma | 2017-02 | PHASE3 |
| NCT02262455 | Santa Maria Biotherapeutics | Ovarian Cancer|Fallopian Tube Cancer|Endometrial Cancer|Solid Tumors | 2014-10 | PHASE1 |
| NCT00248248 | Southeastern Gynecologic Oncology|Ortho Biotech, Inc. | Ovarian Neoplasm | 2005-10 | PHASE2 |
| NCT06516978 | The First Affiliated Hospital with Nanjing Medical University | Diffuse Large B Cell Lymphoma | 2024-10-01 | PHASE2 |
| NCT00003243 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) | Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Diseases | 1998-01 | PHASE1 |
| NCT00016406 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Breast Cancer | 2001-05 | PHASE3 |
| NCT01670084 | Mayo Clinic | B-cell Adult Acute Lymphoblastic Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia | 2012-12 | PHASE2 |
| NCT01004978 | National Cancer Institute (NCI) | Hepatocellular Carcinoma|Unresectable Hepatocellular Carcinoma | 2009-10-28 | PHASE3 |
| NCT06564038 | AstraZeneca | Chronic Lymphocytic Leukaemia|Small Lymphocytic Lymphoma|Mantle-cell Lymphoma|Large B-cell Lymphoma|B-cell Non-Hodgkin Lymphoma | 2025-01-30 | PHASE1|PHASE2 |
| NCT00002611 | Children´s Oncology Group|National Cancer Institute (NCI) | Kidney Cancer | 1995-07 | PHASE3 |
| NCT00004930 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) | Lung Cancer|Metastatic Cancer | 1999-07 | PHASE1 |
| NCT00314977 | Radboud University Medical Center|Sanofi|Amgen | Breast Cancer | 2006-02 | PHASE3 |
| NCT05112536 | G1 Therapeutics, Inc. | Triple Negative Breast Cancer|Breast Cancer | 2022-03-03 | PHASE2 |
| NCT06191744 | Genmab|AbbVie | Follicular Lymphoma (FL) | 2024-02-05 | PHASE3 |
| NCT03542669 | Peking University People´s Hospital|Beijing Weixiao Biotechnology Development Limited | Recurrent Ovarian Carcinoma|Platinum-resistant Ovarian Cancer | 2018-08-03 | PHASE1 |
| NCT02486952 | Hoffmann-La Roche|Serbian Lymphoma Group | Lymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin´s Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma | 2005-08 | |
| NCT03908528 | Damanhour University | Breast Cancer|Chemotherapeutic Toxicity | 2019-03-01 | NA |
| NCT06451302 | Yizhuo Zhang | Ewing Sarcoma|Risk Stratification | 2024-04-17 | NA |
| NCT00087178 | NSABP Foundation Inc|National Cancer Institute (NCI) | Breast Cancer | 2004-05 | PHASE3 |
| NCT03553238 | Nanfang Hospital, Southern Medical University | Leukemia, Acute|Leukemia, T Cell|Leukemia, Lymphoblastic | 2016-02-14 | PHASE2|PHASE3 |
| NCT00264953 | University of Cologne | Hodgkin?s Lymphoma | 1998-05 | PHASE3 |
| NCT00441168 | Janssen-Cilag International NV | Multiple Myeloma | 2006-12 | PHASE2 |
| NCT00199069 | Goethe University|Deutsche Krebshilfe e.V., Bonn (Germany) | Adult Acute Lymphocytic Leukemia | 1993-04 | PHASE4 |
| NCT01070862 | University Hospital, Caen|Laphal | Multiple Myeloma de Novo Treatment | 2003-05 | PHASE3 |
| NCT00204646 | University Hospital Tuebingen | Sarcoma, Soft Tissue | 1999-02 | PHASE2 |
| NCT00199056 | Goethe University | Adult Acute Lymphocytic Leukemia | 1999-10 | PHASE4 |
| NCT00871013 | University of Arkansas | Myeloma | 2009-03 | PHASE2 |
| NCT02471820 | Meletios A. Dimopoulos | Multiple Myeloma | 2014-11 | PHASE2 |
| NCT03527628 | King Abdullah International Medical Research Center | Classical Hodgkin Lymphoma|Hodgkin Lymphoma (Category)|Hodgkin Disease|Hodgkin Lymphoma | 2018-01-01 | PHASE2 |
| NCT00198991 | Goethe University|Deutsche Krebshilfe e.V., Bonn (Germany)|German Federal Ministry of Education and Research | Adult Acute Lymphocytic Leukemia | 2003-04 | PHASE4 |
| NCT00319865 | Korean Multiple Myeloma Working Party|Celgene Corporation | Multiple Myeloma | 2005-11 | PHASE2 |
| NCT05747521 | Henan Cancer Hospital | Soft Tissue Sarcoma | 2021-04-29 | NA |
| NCT00199017 | Johann Wolfgang Goethe University Hospital | Lymphoma, Lymphoblastic | 2004-04 | PHASE4 |
| NCT00199004 | Johann Wolfgang Goethe University Hospital | Adult Acute Lymphocytic Leukemia | 2004-04 | PHASE4 |
| NCT00199082 | Nicola Goekbuget | Burkitt´s Lymphoma|Burkitt´s Leukemia|Mediastinal Neoplasms|Lymphoblastic Lymphoma|Large Cell Anaplastic Lymphoma | 2002-07 | PHASE4 |
| NCT05125939 | Evergreen General Hospital, Taiwan|E-DA Hospital|E-Da Dachang Hospital|Chang Gung Memorial Hospital|Sepulveda Ambulatory Care Center, Veterans Affairs Greater Los Angeles Healthcare System | Adenoma Detection Rate|Colonoscopy | 2021-11-20 | |